J M Smucker Co vs 10X Genomics Inc — how do they compare? J M Smucker Co trades at $119.83 (market cap $12.76B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: J M Smucker Co is the larger of the two by market cap, and J M Smucker Co pays a 3.75% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold J M Smucker Co for 74 Days and 10X Genomics Inc for 91 Days on average.
| SJM | TXG | |
|---|---|---|
Market Cap | $12.76B | $10.07B |
Volume | 1,300,545 | 5,657,286 |
Sector | Consumer Staples | Health |
52-Week High | $132.34 | $97.74 |
52-Week Low | $89.53 | $11.48 |
Typical Hold Time | 74 Days | 91 Days |
Enterprise Value | $19.61B | $9.59B |
Dividend Yield | 3.75% | — |
Signals from Pluang's Aura AI — not financial advice
SJM trades at $119.83, up 3.36% today, with a bullish technical signal and recent earnings beats. The company reported strong Q2 2026 EPS of $3.24 versus $2.22 expected, though 2025 net income was negative $1.23B. Valuation ratios include a P/E of 55.8 and P/S of 1.39, with analyst consensus price target at $138.23.
Outlook is positive with raised 2027 guidance, but risks include volatile profitability and high debt. The stock offers a dividend yield from the upcoming $1.12 payment, supported by institutional buying. Earnings momentum and brand strength provide upside, yet margin pressures and competitive threats remain key watchpoints.
TXG trades at $80.65, up 5.98% on the day, showing strong recent momentum despite a bearish technical signal. The company reported revenue of $642.82M for 2025 with a gross margin of 70.03%, but remains unprofitable with a net loss of $43.54M. Recent news highlights the launch of the Atera spatial biology platform and a patent victory, signaling innovation and competitive strength. Analyst consensus is mixed with a $74.30 price target below the current price, indicating caution on valuation.
The outlook for TXG hinges on commercial execution of new products like Atera to drive revenue growth and a path to profitability. Investment opportunity lies in its leading technology platform and expanding market demand in genomics. Key risks include persistent losses, high valuation multiples, and competitive pressures in the life sciences tools sector. The stock's recent rally faces a test near technical resistance at $81.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →